Sotera Health Company Common Stock
Here’s whether Sotera Health Company Common Stock (SHC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.85% over 10 days); strong 1-year return of +22.9%; 3-month momentum positive (+25.0%). Concerns: RSI 73 — overbought, elevated pullback risk. Currently 1.4% off its 52-week high. Score: +5/7.
SHC is in a confirmed uptrend, trading above both its 50-day ($17.74) and 200-day ($16.65) moving averages. With an RSI of 73.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +22.9% compares to +20.5% for SPY (beat the market by 2.4%).